DANAHER CORP /DE/ News
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, municipal, industrial, and natural resource applications. It also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. The company was founded in 1969 and is headquartered in Washington, the District of Columbia.
see moreDANAHER CORP /DE/ Market News
10d
Deadline Passed for Danaher $172.5M Investor Settlement Claim – What You Need to Know
- The deadline to file a claim for the Danaher $172.5 million securities settlement was September 20, 2026. Here's what investors should know now.
24d
Danaher (DHR) Approves $0.40 Dividend Amid CEO Transition as Stock Holds Steady
Danaher’s board has declared a $0.40 per‑share dividend ahead of its October 30 payment, coinciding with a CEO transition—shares trade near $215.84.
07 Sep at 23:18
WHO Grants Emergency Use Listing for Cepheid Ebola Test in DRC: What It Means for Danaher
The WHO’s September 3 emergency use listing of Cepheid’s Ebola panel in the DRC underscores Danaher’s diagnostic leadership and global impact.
24 Aug at 23:18
Danaher Appoints Julie Sawyer Montgomery as CEO Amid Masimo Integration and Q2 Strength
Danaher (DHR) named Julie Sawyer Montgomery CEO effective October 1, 2026, as the company progresses Masimo integration following strong Q2 results.
29 Jul at 16:30
Danaher Corporation's Q2 2026 Earnings and Strategic Moves Amid Market Volatility
Danaher reports strong Q2 2026 earnings; stock faces market volatility.